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Abstract
Purpose: This study seeks to assess the impact of dedicated brain positron emission
tomography (PET) with 2-deoxy-2-[
18F]fluoro-D-glucose on intended management of patients
with primary and metastatic brain tumors.
Procedures: We analyzed demographic characteristics and evaluated change in intended
management after PET, using previously described metrics, for patients in the National
Oncologic PET Registry (NOPR) undergoing dedicated brain PET. For cases of primary brain
tumors, comparisons to the overall NOPR cohort were made.
Patient Profile: Between December 2006 and April 2009, 509 dedicated brain PET scans were
done on 479 patients—367 (72.1%) for suspected or proven primary brain tumors and 142
(27.9%) for brain metastases. Compared with the overall NOPR cohort, subjects in the
dedicated brain cohort were younger (41.3% less than 65 years vs. 10.5% overall, pG0.0001)
and more frequently had functional limitations from their cancers (78.6% vs. 62.3% overall; odds
ratio (OR) 2.2, 95% CI 1.8–2.8).
Results: The pre-PET patient management plans in the primary brain tumor and metastasis
subgroups were similar. A pre-PET plan of tissue biopsy was slightly more frequent than one of
the treatments (31.3% vs. 28.6%) in the primary brain tumor subgroup and was more common
than in the overall NOPR cohort (14.2%; OR 2.8, 95% CI 2.2–3.5). Changes from treatment to
non-treatment also were more frequent than in the overall NOPR cohort (13.4% vs. 7.7%; OR
1.9, 95% CI 1.3–2.5).
Conclusions: Among NOPR patients, dedicated brain PET was associated with similar net
changes in intended management as in the overall NOPR cohort. However, brain PET patients
were younger, more likely to be symptomatic, and less likely to have a change in management
from non-treatment to treatment as a post-PET plan.
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T
he role of 2-deoxy-2-[
18F]fluoro-D-glucose positron
emission tomography (FDG-PET) in the management
of malignant brain tumors is uncertain [1]. Advocates of
PET suggest that it has several roles complementary to those
of magnetic resonance imaging (MRI) and computed
tomography (CT) in the evaluation of patients with primary
or metastatic tumors of the brain [2, 3]. These complemen-
tary roles reflect PET’s unique ability to assess tissue
glucose utilization, which facilitates evaluation of tumor
grade, identification of optimal sites for stereotactic biopsy
and determination of prognosis during the initial evaluation
of patients with brain tumors. As a tool for evaluation
following treatment, PET can also be useful for detecting
residual tumor after surgery, distinguishing between radia-
tion necrosis and recurrent tumor [4], and monitoring tumor
progression. Additionally, in patients with presumed meta-
static lesions to the brain seen on MRI, whole-body PET
may be useful in determining the origin of unidentified
primary tumors [1].
Since 2006, the National Oncologic PET Registry
(NOPR) has collected data on Medicare beneficiaries with
known or suspected cancers undergoing PET for a wide
variety of uncommon cancer types, including brain cancers,
under Centers of Medicare and Medicaid Services policy
called “coverage with evidence development” [5–7]. We
have previously reported findings from NOPR on the impact
of whole-body PET on intended management in patients
with proven or suspected cancer. We found that the effect of
PET on changing intended management was highly con-
sistent across cancer types and indications [8, 9].
The objective of this study is to assess the impact of
dedicated brain PET on intended patient management in
patients with primary and metastatic brain tumors based on
data in the NOPR.
Patients and Methods
The NOPR is a prospective data registry that collects information
from the PET facility, the physician requesting the PET scan, and
the interpreting physician’s PET report. Detailed descriptions of
NOPR operations, human subject protection procedures, and results
for the impact of PET on physicians’ intended management were
reported previously [8–10].
In brief, the PET facility is responsible for collecting informa-
tion from the referring physician on a pre-PET form and a post-PET
form. The pre-PET form focuses on information regarding the
specific indication for testing, the patient’s cancer type (if known)
and working stage assessment, the patient’s performance status,
whether the referring physician will also be the treating physician,
and the referring physician’s management plan if PET was not
available. Once the PET scan has been completed, the PET facility
uploads the PET report to the database. The final step is the
completion of the post-PET form by the referring physician to
assess the management plan in light of the PET findings.
The primary endpoint was the impact of PET on physicians’
intended management dichotomized as either treatment (e.g., surgery,
chemotherapy,radiation,or othertreatment,aloneor incombination)or
non-treatment (e.g., observation, alternative imaging or other non-
invasive testing, biopsy, or supportive care). A change in management
was defined as a switch from treatment to non-treatment or vice versa.
NOPR began enrolling patients in May 2006. In December
2006, the data collection procedures were changed to stratify the
PET imaging procedures into three categories: body PET (or PET/
CT), dedicated brain PET only, or both body PET (or PET/CT) and
dedicated brain PET. This analysis uses only cases of dedicated
brain PET (CPT® code 78608) because where both body and
dedicated brain imaging were performed, the referring physician’s
responses did not discriminate the impact of each component on
intended management. The cohort does not include cases where a
body PET or PET/CT acquisition (CPT® codes 78811–78816)
included the entire brain. In addition, cases where PET was
requested for monitoring of ongoing treatment were excluded.
Statistical Analysis
A change in intended management after PET was modeled as
binary variable on the basis of a binomial distribution. Changes
were defined at the PET scan level and were assumed to be
independent for different patients or indication for testing.
For the comparison of the change of intended management in the
dedicated brain PET cohort with that in the overall NOPR cohort
(excluding treatment monitoring), we used chi-square analysis. For
thesecomparisons,werestricted our study population tothose patients
with primary brain tumors, excluding patients with proven or
suspected brain metastases because of the small number of the latter.
Odds ratios (ORs) were calculated to quantify the association between
two binary variables. The 95% confidence intervals are constructed
withtheexactmethodforbinomialdistribution.Allstatisticalanalyses
were carried out using SAS version 9.1 (SAS Institute, Cary, NC).
Results
This report includes data from 509 dedicated brain PET scans
performed between December 1, 2006 and April 3, 2009 on
479 patients. During the same interval, additional four studies
involving both body PET (or PET/CT) and dedicated brain
PET were performed in two patients. The entire NOPR cohort
for this period consisted of 74,932 scans in 62,122 patients.
The clinical profile of the cohort is summarized in Table 1.
The referring physicians recorded the cancer type as primary
brain tumor (n=367) and brain metastases (n=142), including
suspected or proven brain metastases of unknown primary
origin (n=28). The indication for PET imaging in patients with
primary brain tumors was diagnosis in 21.2%, initial staging in
4.1%, restaging in 16.6%, and detection of suspected recur-
rence in 58.0%. Thirty-seven cases, where the pre-PET form
indicated that the patient had a primary brain tumor, were
reclassified as suspected or proven brain metastases since the
summary stage on the pre-PET form stated that the patient
already had known non-brain metastatic sites. Eighty percent
of the scans were performed with PET/CT scanners.
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brain-only cohort were younger (41.3% less than 65 years
vs. 10.5% overall, pG0.0001) and more often symptomatic
from their cancers [ECOG] performance score ≥1 in 78.6%
vs. 62.3% overall (OR 2.2, 95% CI 1.8–2.8) or ≥2 in 25.5%
vs. 12.6% overall (OR 2.4, 95% CI 1.9–2.9).
The pre-PET management plans in the primary brain
tumor and metastasis subgroups were similar. The most
frequent plan of intended management before PET, assum-
ing PET was not available, was alternative imaging. For the
primary tumor tumor-only subgroup, the pre-PET plan was
slightly more frequently tissue biopsy than treatment (31.3%
vs. 28.6%); this frequency of planned biopsy if PET was not
available was more common than in the overall NOPR
cohort (14.2%; OR 2.8, 95% CI 2.2–3.5).
Outcome Results
Table 2 summarizes the changes in intended management
when the pre- and post-PET plans were classified as
treatment vs. non-treatment. The frequency of change in
intended management associated with PET was 38.2% in the
primary brain tumor subgroup and 35.2% in the brain
metastasis subgroup. The frequency of change in the primary
brain tumor subgroup was similar to that in the overall
NOPR cohort (37.0%; OR=1.1, 95% CI 0.8–1.3).
In the primary brain tumor subgroup, there were modest
differences when comparing scans done for diagnosis or
initial staging (n=93) vs. restaging or detection of suspected
recurrence (n=274). Any form of treatment as the post-PET
plan was slightly more common in restaging/suspected
recurrence cases (41.7%) than in diagnosis/initial staging
cases (35.5%). Overall, changes from treatment to non-
treatment were more frequent in the primary brain tumor
subgroup than in the overall NOPR cohort (13.4% vs. 7.7%;
OR 1.9, 95% CI 1.3–2.5).
Table 3 summarizes the changes in intended manage-
ment when stratified by specific intended actions for the
two brain tumor subgroups. For both subgroups, the two
most frequent pre-PET strategies—tissue biopsy or alter-
native imaging—involved additional data gathering. Post-
PET, the intended management was revised in more than
Table 1. Profile of dedicated brain PET studies in NOPR
Primary brain tumors Proven or suspected brain metastasis
Number % Number %
Total scans (Total patients) 367 (343) 142 (139)
Age, mean (years) 61.8 67.9
Median 66 70
Range 25–97 29–88
Primary site of metastases to brain
Unknown primary NA
a 28 26.7
Lung, small cell NA 14 13.3
Prostate NA 12 11.4
Kidney and other urinary tract NA 9 8.6
Ovary and uterine adnexa NA 6 5.7
Other NA 36 34.
Performance status (ECOG scale)
Asymptomatic: fully active (0) 76 20.7 33 23.2
Symptomatic, fully ambulatory (1) 196 53.4 74 52.1
Symptomatic in bed G50% of the day (2) 60 16.3 27 19.0
Symptomatic in bed 950% of the day (3) 28 7.6 7 4.9
Bedridden (4) 7 1.9 1 0.7
Indication for PET
Diagnosis 78 21.3
aa
Initial Staging 15 4.1
aa
Restaging 61 16.6
aa
Suspected Recurrences 213 58.0
aa
Pre-PET stage
No evidence of disease/remission 17 4.6 3 2.1
Localized only 218 59.4 18 12.6
Regional 24 6.5 6 4.2
Single site of metastasis NA 45 31.6
Multiple sites of metastases NA 40 28.1
Unknown or uncertain 108 29.4 30 21.1
Pre-PET intended management
Observation 25 6.8 17 12.0
Additional Imaging 122 33.3 54 38.0
Tissue Biopsy 115 31.3 33 23.2
Treatment 105 28.6 38 26.8
Curative 48 45.7 18 47.4
Palliative 57 54.3 20 52.6
NA not applicable, ECOG Eastern Cooperative Oncology Group
aNot calculated because of reclassification of 37 cases (see text)
B.E. Hillner, et al.: Dedicated Brain PET in NOPR 16380% of cases to either observation or treatment. These
revised post-PET plans were about equally divided
between observation and treatment.
For the primary brain tumor subgroup, a change in the
pre-PET plan from treatment to non-treatment was more
common (46.7%) than the converse (34.7%). Of the primary
brain tumor patients with a pre-PET plan of treatment, the
post-PET plan had a treatment goal change in 28.6%.
Discussion
Dedicated brain PET for the evaluation of suspected or
proven primary brain tumor or brain metastasis represents a
narrow spectrum of the potential uses of PET in oncology.
In part, this reflects the limited sensitivity of FDG imaging
for detection of brain tumors, particularly those with low to
moderate levels of FDG uptake, against a background of
high FDG uptake in normal gray matter [2]. MRI, including
newer perfusion and diffusion methods, has higher sensi-
tivity and is the dominant modality for brain tumor imaging
in current practice [11]. Nonetheless, PET provides comple-
mentary information on cancer metabolism that is correlated
with tumor grade and prognosis at diagnosis and aids in
detecting persistent or recurrent tumor after therapy.
In this report, we describe the experience with oncologic
brain PET among patients participating in the NOPR. This
report represents the largest series, to our knowledge,
addressing the use and impact of dedicated brain PET in
patients with brain tumors. Our data indicate that dedicated
brain PET is used relatively uncommonly for oncologic
indications, accounting for only 0.67% of NOPR PET scans.
While only Medicare beneficiaries were eligible for inclu-
sion in this registry, over 40% of the patients were less than
65 years of age, the usual threshold for Medicare eligibility.
This is likely because younger participants with brain cancer
already had qualified for disability (and thus for Medicare
coverage) as a consequence of their disease. That younger
patients had to demonstrate disability to qualify for Medicare
coverage may explain the higher rates of functional impair-
ment (inferred from ECOG performance scores) observed in
the dedicated brain PET cohort as opposed to the NOPR
population overall (79.3% vs. 64.3%, respectively).
We found that the frequency of change in intended
management associated with dedicated brain PET was
similar to that found overall for the aggregate of other
cancers in NOPR, yet the changes in intended management
as a consequence of PET were less frequently associated
with the initiation of therapy in subjects with brain tumors.
Changes in intended management from treatment to non-
treatment were more frequent than the converse. Among
patients with a pre-PET plan of tissue biopsy, less than 16%
continued to have biopsy as the intended management after
PET. The avoidance of brain biopsy could result in
significant cost savings, but further tracking of Medicare
claims is needed to evaluate if such savings are realized.
A major limitation of the NOPR is the inability to
determine whether the intended changes in management
confer a benefit in long-term outcomes. Furthermore, the
registry cannot document that referring physicians actually
completed the planned management changes. A data linkage
to the Medicare claims of NOPR participants is in process to
address this important question.
Although brain metastases outnumber primary neoplasms
by at least ten to one [12], the use of dedicated brain PET in
NOPR to evaluate suspected metastases was infrequent and
less common than for primary brain tumors. This suggests
that referring physicians were highly selective in their use of
dedicated brain PET among patients with metastatic cancer,
Table 2. Change in intended management
Pre-PET Post-PET Diagnosis or initial staging Restaging or suspected recurrence Known or suspected brain metastasis
Primary brain tumors Primary brain tumors
(n=93) (n=274) (n=142)
Number % Number % Number %
Non-treatment Non-treatment 48 51.6 123 44.9 68 47.9
Treatment Treatment 11 11.8 45 16.4 24 16.9
Non-treatment Treatment 22 23.7 69 25.2 36 25.4
Treatment Non-treatment 12 12.9 37 13.5 14 9.9
Table 3. Impact on intended management strategies associated with dedicated brain PET in NOPR cohort
Change from pre-PET to post-PET plan Primary brain tumors (n=367) Known or suspected brain metastasis (n=105)
Number % Number %
Change from tissue biopsy to an alternative strategy 98/115 85.2 27/33 81.8
Change from additional imaging to an alternative strategy 105/122 86.1 48/54 88.9
Change from treatment to non-treatment 49/105 46.7 14/38 36.8
Change from non-treatment to treatment 91/262 34.7 36/104 34.6
Change in pre-PET treatment goal 16/56 28.6 5/24 20.8
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sensitivity of FDG-PET for detection of brain metastases
[13, 14]. Still, in general the direction and magnitude of
impact of PET on management was similar between groups.
In summary, dedicated brain PET is used very selectively
amongparticipantsofNOPR.Theestimatednationalincidence
of primary brain cancers in the elderly (age over 65 years) is
about 3,600 per year [15]. The NOPR data reported herein
represents about 4% of annual incidence. The NOPR patients
are younger more often functionally impaired from their
disease and rarely undergo a tissue biopsy after PET.
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